AbbVie Inc.
www.abbvie.com
Latest From AbbVie Inc.
AndroGel Competitors Enter US After Perrigo’s Exclusivity Expires
Following the expiry of Perrigo’s 180-day exclusivity for its generic version of AndroGel, firms including Lupin and Teva have launched their own generic testosterone 1.62% gels in the US.
J&J's Spravato's Star Power Rises While Zytiga's Sets
With Spravato's launch underway, J&J reports that 800 sites have been certified to administer the depression drug. Newer drugs drove pharma sales in the first quarter, while US sales of Zytiga declined 55% due to generic competition.
EMA Restricts Sanofi's Lemtrada Use, Initiates Risk-Benefit Review
Labeling changes for the multiple sclerosis drug being mandated by European regulators were made to the US label in January.
US FDA Guidance Production May Be Slowed By New OMB Review Requirement
White House says all guidances, as well as proposed rules, must be submitted to OMB for a determination whether they are major or minor.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
- AbbVie Inc.
- Senior Management
-
Richard A Gonzalez, Chmn. & CEO
William J Chase, EVP, CFO
Michael E Servino, MD, EVP, R&D & CSO
Carlos Alban, EVP, Commercial Ops. - Contact Info
-
AbbVie Inc.
Phone: (847) 937-6100
1 N. Waukegan Rd.
North Chicago, IL 60064
USA
Advertisement
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice